XML 90 R49.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended |  | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |  |  | 1 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2011 | Dec. 31, 2008 Glaxo, Smith, Kline Project | Dec. 31, 2013 Glaxo, Smith, Kline | Dec. 31, 2013 Glaxo, Smith, Kline | Dec. 31, 2012 Glaxo, Smith, Kline | Dec. 31, 2011 Glaxo, Smith, Kline | Dec. 31, 2011 Glaxo, Smith, Kline Expansion | Dec. 31, 2013 Glaxo, Smith, Kline Maximum | Dec. 31, 2013 Glaxo, Smith, Kline Maximum Annual net sales milestones achieved | Dec. 31, 2013 Glaxo, Smith, Kline Minimum | Sep. 30, 2006 Astra Zeneca | Dec. 31, 2013 Astra Zeneca | Dec. 31, 2012 Astra Zeneca | Dec. 31, 2011 Astra Zeneca | Oct. 31, 2011 Amendment | Dec. 31, 2011 Amendment | Dec. 31, 2012 Amendment Advance the program following completion of Phase 2a | Mar. 31, 2012 Amendment Advance the program following completion of Phase 2a | Dec. 31, 2013 Amendment Advance the program following completion of Phase 2a | Dec. 31, 2013 Amendment Maximum Advance the program following completion of Phase 2a | Sep. 30, 2013 Hepatic Fibrosis and Cirrhosis National Institutes of Health | Jun. 30, 2012 Autoimmune Disease National Institutes of Health | May 31, 2012 Rheumatoid Arthritis National Institutes of Health | Jul. 31, 2011 Skin Autoimmune Inflammation National Institutes of Health | Aug. 31, 2010 HBV National Institutes of Health | Jul. 31, 2010 HPV National Institutes of Health | Sep. 30, 2008 ISS Technology National Institutes of Health
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs for research and early clinical development |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  | $ 125,000,000 | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Revenue |  | 10,000,000 |  | 1,702,000 | 1,428,000 | 1,428,000 |  |  |  |  |  | 720,000 | 720,000 | 120,000 | 3,000,000 |  | 6,000,000 | 2,600,000 |  |  |  |  |  |  |  |  |
Revenue from milestone payment | 12,000,000 |  |  |  |  | 15,000,000 | 3,000,000 |  |  |  |  | 2,507,000 | 2,462,000 | 642,000 |  |  |  |  | 20,000,000 | 100,000,000 |  |  |  |  |  |  |
Deferred revenue recognition period |  |  |  |  |  |  |  | 7 years |  | 6 years |  | 50 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional revenue recognized |  |  | 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  | 2,500,000 | 2,500,000 | 4,200,000 |  |  |  |  |  |  | 4,800,000 | 7,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration and license agreement period |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of clinical development activities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 | 600,000 | 400,000 | 600,000 | 1,400,000 | 600,000 |
Contract agreement period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years
Contract awarded to develop technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,000,000

X
- Definition Contract Term + References No definition available. + Details
Name: | dvax_ContractTerm
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Projects + References No definition available. + Details
Name: | dvax_NumberOfProjects
Namespace Prefix: | dvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Milestone Payment Amount + References No definition available. + Details
Name: | dvax_PotentialMilestonePaymentAmount
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research Collaboration and License Agreement Period + References No definition available. + Details
Name: | dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Period + References No definition available. + Details
Name: | dvax_RevenueRecognitionPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 910 -SubTopic 310 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph c -Article 5 + Details
Name: | us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of revenue recognized in earnings during the reporting period associated with arrangements entered into or modified after adoption of the new accounting pronouncement or change in accounting principle. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 65 -Paragraph 1 -Subparagraph (d)(3) -URI http://asc.fasb.org/extlink&oid=19771798&loc=SL6749767-165964 + Details
Name: | us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCurrentPeriodDisclosuresRevenueRecognizedAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration